Press Releases

November 1, 2022
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
September 22, 2022
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
September 1, 2022
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
August 31, 2022
Revolution Medicines to Participate in Upcoming Investor Conferences
August 9, 2022
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
July 28, 2022
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 22, 2022
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 19, 2022
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
July 19, 2022
Revolution Medicines Announces Commencement of Public Offering of Common Stock
July 13, 2022
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors